Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 7/20 | 0.38 |
| ▸ | AVPR1B | P47901 | 7/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | CTSE | P14091 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2497803 | 0.91 | BRD4 (0.46) | BRD4CASP3OXTRAVPR1BAVPR1A | |
| SCHEMBL4590243 | 0.88 | OXTR (0.49) | BRD4OXTRAVPR1BAVPR1A | |
| SCHEMBL2498773 | 0.81 | AVPR1B (0.50) | BRD4CASP3OXTRAVPR1BAVPR1A | |
| SCHEMBL7076240 | 0.80 | AVPR1B (0.47) | BRD4CASP3OXTRAVPR1BAVPR1A | |
| SCHEMBL2499968 | 0.79 | BRD4 (0.49) | BRD4CASP3OXTRAVPR1BAVPR1A | |
| SCHEMBL4590690 | 0.78 | OXTR (0.51) | BRD4OXTRAVPR1BAVPR1A | |
| SCHEMBL4589816 | 0.77 | AVPR1B (0.56) | BRD4OXTRAVPR1BAVPR1AALDH1A1 | |
| SCHEMBL2494928 | 0.77 | AVPR1B (0.56) | BRD4OXTRAVPR1BAVPR1AALDH1A1 | |
| SCHEMBL2500313 | 0.77 | BRD4 (0.41) | BRD4CASP3OXTRAVPR1BAVPR1A | |
| SCHEMBL2492934 | 0.76 | AVPR1A (0.53) | BRD4OXTRAVPR1BAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | AVPR1B, AVPR1A, AVPR2 | BRD4 822/4885CASP3 2314/4885OXTR 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.